Indivior Pharmaceuticals (FRA:E7P) Other Current Receivables: €14 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:E7P Indivior Pharmaceuticals Inc FRA:E7P
71 GF Score
Price €32.80
GF Value €21.12
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Indivior Pharmaceuticals Other Current Receivables?

Indivior Pharmaceuticals FRA:E7P -1.20% 71 Other Current Receivables is €14 Mil as of Jun. 2026. GuruFocus rates FRA:E7P with a GF Score™ of 71/100 and a GF Value™ of €21.12 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Indivior Pharmaceuticals's Other Current Receivables for the quarter that ended in Jun. 2026 was €14 Mil.

Indivior Pharmaceuticals's quarterly Other Current Receivables increased from Dec. 2025 (€1.71 Mil) to Mar. 2026 (€10.38 Mil) and increased from Mar. 2026 (€10.38 Mil) to Jun. 2026 (€13.89 Mil).

Indivior Pharmaceuticals's annual Other Current Receivables increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€32.47 Mil) but then declined from Dec. 2024 (€32.47 Mil) to Dec. 2025 (€1.71 Mil).

Indivior Pharmaceuticals Other Current Receivables Related Terms

Indivior Pharmaceuticals Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Indivior Pharmaceuticals's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indivior Pharmaceuticals Other Current Receivables Chart

Indivior Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.51 4.72 0.00 32.47 1.71

Indivior Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.60 11.08 1.71 10.38 13.89
FRA:E7P
71GF Score
Indivior Pharmaceuticals Inc FRA:E7P
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indivior Pharmaceuticals Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €14 Mil mean?
Indivior Pharmaceuticals (FRA:E7P) has a Other Current Receivables of €14 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Indivior Pharmaceuticals and its competitors.
Is Indivior Pharmaceuticals' Other Current Receivables too high?
Indivior Pharmaceuticals' current Other Current Receivables is €14 Mil. Overall, Indivior Pharmaceuticals has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' Other Current Receivables compare to KNSA and AMRX?
Indivior Pharmaceuticals' Other Current Receivables of €14 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Indivior Pharmaceuticals and its competitors. Indivior Pharmaceuticals's current Other Current Receivables is €14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (FRA:E7P) is currently considered Significantly Overvalued. The stock's GF Value™ is €21.12, compared to a current price of €32.80 — trading 55.3% above its estimated fair value. The current Other Current Receivables is €14 Mil. Indivior Pharmaceuticals' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Indivior Pharmaceuticals (FRA:E7P), the current Other Current Receivables is €14 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indivior Pharmaceuticals (FRA:E7P) Overvalued in 2026?

Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued. The current stock price of €32.80 is trading 55.3% above its estimated GF Value™ of €21.12. GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:E7P:

  • Other Current Receivables: €14 Mil
  • GF Value™: €21.12 vs. price of €32.80 (55.3% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the FRA:E7P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Indivior Pharmaceuticals Business Description

Other Exchanges INDV:USA
Address 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
71GF Score

Get the complete analysis for FRA:E7P

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.80
Price
€21.12
GF Value